.jpg "Reading culture in the digital age")
.jpg "What to see in Hai Duong newspaper on April 21?")
-a9f705f0fc2bb442b889e7ca8cfb4e9f.jpg "Prime Minister directs early payment of pensions in May")
.jpg "Parishioners joyfully celebrate Easter at Hai Duong Church")
Submit a comment
On February 8, British pharmaceutical company AstraZeneca announced that its annual profit would nearly double to $6 billion by 2023.
Positive signals from the cancer treatment division helped offset the decline in sales of COVID-19 treatment drugs.
Specifically, the company's revenue in 2023 increased 3% compared to a year ago to nearly $46 billion. Notably, the cancer treatment division witnessed a 23% increase in sales, while sales of COVID-19 treatment drugs decreased by more than $3.7 billion.
In the results report, CEO Pascal Soriot said that 2023 was a year of scientific progress. This was also a year when AstraZeneca showed good financial performance with double-digit revenue growth, especially on the occasion of its 25th anniversary. He expected the company to continue its breakthrough growth in 2024 thanks to the dissemination of drugs to all regions of the world.
According to Mr. Soriot, AstraZeneca's continued development and diversification of its drug portfolio, its global reach, and its research and development processes will be the driving force for the company to maintain its leading position in the industry's growth momentum.
